Skip to main content

Table 1 Surviving fraction and micronucleus frequency at 0 Gy

From: The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy

  Total tumor cells Quiescent cells
<Plating efficiency (%)>   
Without 10B-carrier 70.7 ± 8.8a ----
BPAb (250 mg/kg) 45.5 ± 5.8 ----
BPA (500 mg/kg) 40.5 ± 4.6 ----
BPA (750 mg/kg) 39.4 ± 3.8 ----
BSHc (125 mg/kg) 54.0 ± 6.8 ----
BSH (250 mg/kg) 50.0 ± 5.8 ----
BSH (325 mg/kg) 44.8 ± 4.8 ----
<Micronucleus frequency>   
Without 10B-carrier 0.029 ± 0.007 0.053 ± 0.007
BPA (250 mg/kg) 0.045 ± 0.010 0.067 ± 0.008
BPA (500 mg/kg) 0.050 ± 0.011 0.073 ± 0.009
BPA (750 mg/kg) 0.054 ± 0.012 0.078 ± 0.012
BSH (125 mg/kg) 0.042 ± 0.005 0.069 ± 0.011
BSH (250 mg/kg) 0.047 ± 0.005 0.075 ± 0.010
BSH (325 mg/kg) 0.052 ± 0.007 0.081 ± 0.012
  1. a; Mean ± standard error (n = 9).
  2. b; Boronophenylalanine-10B.
  3. c; Sodium mercaptododecaborate-10B.
  4. The values of the plating efficiencies and micronucleus frequencies for the combination with the 10B-carrier were significantly lower and higher than those for no combination with the 10B-carrier, respectively.
  5. The values of the micronucleus frequencies for quiescent cells were significantly higher than those for total tumor cells.